LC-MS/MS Method Development and Validation for Quantification of Lenvatinib in K2EDTA Human Plasma: A Comprehensive Review

https://doi.org/10.61096/ijphr.v14.iss4.2026.1042-1053

Authors

  • B. Nikhitha Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • Duddagi Suchitra Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • K. Neelima Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • P. Vivek Sagar Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India

Keywords:

Lenvatinib, LC-MS/MS, K₂EDTA plasma, bioanalytical method validation, ICH M10, therapeutic drug monitoring, tyrosine kinase inhibitor

Abstract

Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET and KIT, used in radioiodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial carcinoma. Its pharmacokinetics vary widely between patients, more than 60% of patients need dose reduction or interruption, and exploratory trough targets of about 40–90 ng/mL have been proposed. These features have driven the development of LC-MS/MS methods for plasma quantification in support of clinical pharmacology and therapeutic drug monitoring (TDM).

This review surveys the bioanalytical methods published for lenvatinib between 2012 and 2026. It covers single-analyte LC-MS/MS methods in plasma and serum, the sponsor's multi-laboratory validation and cross-validation, multi-analyte TKI panels, methods for total and unbound drug, microsampling (dried blood spots), HPLC-UV and preclinical methods. For each, sample volume, anticoagulant, extraction, internal standard, chromatography, MS transitions, calibration range and validation findings are summarised.

The literature shows that protein precipitation with a stable-isotope-labelled internal standard and a short C18 gradient can meet TDM needs over 0.5–2000 ng/mL. However, most methods used sodium-heparin plasma, only one plasma method reports K₂EDTA, several calibration ranges do not bracket the clinical trough window, matrix effects are often large, and no single-analyte method has been validated under ICH M10. A strategy for a K₂EDTA human plasma method aligned with ICH M10 is proposed.

Dimensions

Published

2026-11-13

How to Cite

B. Nikhitha (2026) “LC-MS/MS Method Development and Validation for Quantification of Lenvatinib in K2EDTA Human Plasma: A Comprehensive Review”, International Journal of Pharmaceuticals and Health Care Research, 14(4), pp. 1042–1053. doi: 10.61096/ijphr.v14.iss4.2026.1042-1053.

Issue

Section

Articles